PFIZER INC Segment Reporting Information, Expenditures for Additions to Long-Lived Assets (Deprecated 2011-01-31)
PFIZER INC (PFE) reported Segment Reporting Information, Expenditures for Additions to Long-Lived Assets (Deprecated 2011-01-31) of $1.51 billion for the 12-month period ending 2010-12-31, per its 10-K filed 2011-02-28.
Discontinued › Notes › Segment Reporting
us-gaap:SegmentReportingInformationExpendituresForAdditionsToLongLivedAssets · last filed 2011-02-28
- PFIZER INC segment reporting information, expenditures for additions to long-lived assets (deprecated 2011-01-31) for fiscal 2010 was $1.51B, a 25.56% increase from fiscal 2009.
- PFIZER INC segment reporting information, expenditures for additions to long-lived assets (deprecated 2011-01-31) for fiscal 2009 was $1.21B, a 29.16% decline from fiscal 2008.
- PFIZER INC segment reporting information, expenditures for additions to long-lived assets (deprecated 2011-01-31) for fiscal 2008 was $1.70B.
| Period end | Segment Reporting Information, Expenditures for Additions to Long-Lived Assets (Deprecated 2011-01-31) 12 month |
|---|---|
| 2010-12-31 | $1.51B 10-K · filed 2011-02-28 |
| 2009-12-31 | $1.21B 10-K · filed 2011-02-28 |
| 2008-12-31 | $1.70B 10-K · filed 2011-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |